Mochi’s tirzepatide page is explicit that the starting medication quote excludes membership and can change with dose. It is a compounded preparation, so comparing it with Zepbound requires more than subtracting prices.
- Reviewed product
- Compounded tirzepatide injection
- Public price boundary
- Starting medicine quote $90; membership additional
- Prescription
- Required; eligibility determined clinically
- Research date
- October 8, 2026
Identify the exact product
The provider describes a weekly compounded tirzepatide injection prescribed at clinician discretion. The medication page lists a starting quote of $90 and separately states the membership requirement. It also explains that medicine cost is not included in the membership fee.[source]
What the evidence applies to
FDA’s concerns about unapproved GLP-1 products apply to the category, including quality review, dosing errors and the need for an appropriate patient-specific reason for compounding. This review does not treat a compounded product as a generic approved tirzepatide drug.[source]
Understand the complete cost
Ask for a written total that combines membership, medicine, any necessary supplies and the selected billing term. Confirm what happens financially if the prescribed treatment changes. A quote at the lowest listed starting level is not a prediction of every later bill.[source]
Care, refills and practical details
The page describes a live visit and continuing access to a care team. Verify appointment availability and the channel for clinical questions. A platform may coordinate care through affiliated practices; it is useful to know who actually prescribes and which pharmacy dispenses.[source]
Safety questions come before the price
FDA has identified concerns including dosing errors, inappropriate dose escalation and unapproved salt forms in the compounded GLP-1 market. Obtain treatment through a licensed prescriber and pharmacy, and ask why an approved drug cannot meet the clinical need. These medicines can have serious adverse effects; a low price is not a safety assessment.[source]
Compare a genuinely similar option
LillyDirect’s branded Zepbound pricing is a useful approved-product benchmark, with separate care arrangements to consider. CoreAge Rx’s compounded tirzepatide has a different advertised package. Neither comparison can be completed from medication starting quotes alone.
Read the full provider review and the total-cost guide before treating any headline as the complete treatment budget.
Your questions, answered
Is the displayed price my guaranteed total?
No. It is the public price boundary recorded on the review date. The prescribed product, dose, membership, billing period and eligibility can change the amount you pay.
Did you buy or test this treatment?
No. This is a source-based product and access review. We did not obtain a prescription, purchase medication or independently test treatment results.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Accessed October 8, 2026.
- Mochi: compounded tirzepatideStarting medication quote; dose-dependent; membership extra
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags
- NIDDK: prescription medicines for overweight and obesityEligibility, long-term care, treatment context and insurance questions